{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:09:42Z","timestamp":1792404582325,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>There is a need for early quantitative markers of potential treatment response in patients with hereditary transthyretin (ATTRv) amyloidosis to guide therapy. This study aims to evaluate changes in cardiac tracer uptake on bone scintigraphy in ATTRv amyloidosis patients on different treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective cohort study, outcomes of 20 patients treated with the transthyretin (<jats:italic>TTR)<\/jats:italic> gene silencer patisiran were compared to 12 patients treated with a TTR-stabilizer. Changes in NYHA class, cardiac biomarkers in serum, wall thickness, and diastolic parameters on echocardiography and NYHA class during treatment were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median heart\/whole-body (H\/WB) ratio on bone scintigraphy decreased from 4.84 [4.00 to 5.31] to 4.16 [3.66 to 4.81] (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001) in patients treated with patisiran for 29 [15\u201334] months. No changes in the other follow-up parameters were observed. In patients treated with a TTR-stabilizer for 24 [20 to 30] months, H\/WB ratio increased from 4.46 [3.24 to 5.13] to 4.96 [ 3.39 to 5.80] (<jats:italic>p<\/jats:italic>\u2009=\u2009.010), and troponin T increased from 19.5 [9.3 to 34.0] ng\/L to 20.0 [11.8 to 47.8] ng\/L (<jats:italic>p<\/jats:italic>\u2009=\u2009.025). All other parameters did not change during treatment with a TTR-stabilizer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A change in cardiac tracer uptake on bone scintigraphy may be an early marker of treatment-specific response or disease progression in ATTRv amyloidosis patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06459-y","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:01:21Z","timestamp":1697428881000},"page":"681-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8572-9428","authenticated-orcid":false,"given":"H. S. A.","family":"Tingen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8414-958X","authenticated-orcid":false,"given":"A.","family":"Tubben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0375-4460","authenticated-orcid":false,"given":"J.","family":"Bijzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1493-2998","authenticated-orcid":false,"given":"M. P.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-4413","authenticated-orcid":false,"given":"P.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Houwerzijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. L. H.","family":"Muntinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-0321","authenticated-orcid":false,"given":"P. A.","family":"van der Zwaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8081-0641","authenticated-orcid":false,"given":"A. W. J. M.","family":"Glaudemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-518X","authenticated-orcid":false,"given":"M. I. F. J.","family":"Oerlemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5457-3010","authenticated-orcid":false,"given":"C.","family":"Knackstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-0431","authenticated-orcid":false,"given":"M.","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3315-2006","authenticated-orcid":false,"given":"A.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1827-0482","authenticated-orcid":false,"given":"B. P. C.","family":"Hazenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-1164","authenticated-orcid":false,"given":"R. H. J. A.","family":"Slart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-6830","authenticated-orcid":false,"given":"H. L. A.","family":"Nienhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"6459_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15:387\u2013404.","journal-title":"Nat Rev Neurol"},{"key":"6459_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.amjcard.2017.09.029","volume":"121","author":"SHC Klaassen","year":"2018","unstructured":"Klaassen SHC, Tromp J, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, et al. Frequency of and prognostic significance of cardiac involvement at presentation in hereditary transthyretin-derived amyloidosis and the value of N-terminal Pro-B-type natriuretic peptide. Am J Cardiol. 2018;121:107\u201312.","journal-title":"Am J Cardiol"},{"key":"6459_CR3","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42:1554\u201368.","journal-title":"Eur Heart J"},{"key":"6459_CR4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404\u201312.","journal-title":"Circulation"},{"key":"6459_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial and long-term extension study. Eur J Heart Fail. 2021;23:277\u201385.","journal-title":"Eur J Heart Fail"},{"key":"6459_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","volume":"26","author":"G Lohrmann","year":"2020","unstructured":"Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, et al. Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Cardiac Fail. 2020;26:753\u20139.","journal-title":"J Cardiac Fail"},{"key":"6459_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/13506129.2014.997872","volume":"22","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y, Tojo K, Morita H, Koyama J, Ikeda S. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015;22:79\u201383.","journal-title":"Amyloid"},{"key":"6459_CR8","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658.","journal-title":"JAMA"},{"key":"6459_CR9","doi-asserted-by":"crossref","unstructured":"Coelho T, Maia LF, Martins da Silva, A. Tafamidis for transthyretin familial amyloid polyneuropathy. Neurology. 2012;79(8):785\u201392.","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"6459_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang C-C, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"6459_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO study. Circulation. 2019;139:431\u201343.","journal-title":"Circulation"},{"key":"6459_CR12","doi-asserted-by":"crossref","unstructured":"Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC: Cardiovascular Imaging. 2021;14:189\u201399.","DOI":"10.1016\/j.jcmg.2020.07.043"},{"key":"6459_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid. 2020;27:52\u20138.","journal-title":"Amyloid"},{"key":"6459_CR14","unstructured":"Maurer, MS, Fontana M, Berk JL. (September 4\u20138, 2022) Primary results from APOLLO-B, a phase 3 study of patisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy [Conference presentation]. XVII Meeting of the International Society of Amyloidosis (ISA) 2022. Heidelberg."},{"key":"6459_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, Coelho T, Plant\u00e9-Bordeneuve V, Berk JL, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30:1\u20139.","journal-title":"Amyloid"},{"key":"6459_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14.","journal-title":"J Am Soc Echocardiogr"},{"key":"6459_CR17","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"6459_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12350-019-01643-w","volume":"28","author":"C Gallini","year":"2021","unstructured":"Gallini C, Tutino F, Martone R, Ciaccio A, Costanzo EN, Taborchi G, et al. Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy. J Nucl Cardiol. 2021;28:90\u20139.","journal-title":"J Nucl Cardiol"},{"key":"6459_CR19","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s12350-015-0261-x","volume":"23","author":"A Casta\u00f1o","year":"2016","unstructured":"Casta\u00f1o A, DeLuca A, Weinberg R, Pozniakoff T, Blaner WS, Pirmohamed A, et al. Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol. 2016;23:1355\u201363.","journal-title":"J Nucl Cardiol"},{"key":"6459_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.mayocp.2019.10.036","volume":"95","author":"D Groothof","year":"2020","unstructured":"Groothof D, Nienhuis HLA, Bijzet J, Houwerzijl EJ, van den Berg MP, Glaudemans AWJM, et al. Regression of bone-tracer uptake in cardiac transthyretin amyloidosis. Mayo Clin Proc. 2020;95:417\u20138.","journal-title":"Mayo Clin Proc"},{"key":"6459_CR21","doi-asserted-by":"publisher","unstructured":"Rettl R, Wollenweber T, Duca F, Binder C, Cherouny B, Dachs TM, Camuz Ligios L, Schrutka L, Dalos D, Beitzke D, Loewe C, Badr Eslam R, Kastner J, Hacker M, Bonderman D. Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24(8):1019\u20131030. https:\/\/doi.org\/10.1093\/ehjci\/jead030.","DOI":"10.1093\/ehjci\/jead030"},{"key":"6459_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12350-022-03137-8","volume":"30","author":"S Maeda-Ogata","year":"2023","unstructured":"Maeda-Ogata S, Tahara N, Tahara A, Bekki M, Honda A, Sugiyama Y, et al. Treatment response to Tafamidis quantitatively assessed by serial bone scintigraphy in transthyretin amyloid cardiomyopathy. J Nucl Cardiol. 2023;30:403\u20134.","journal-title":"J Nucl Cardiol"},{"key":"6459_CR23","doi-asserted-by":"publisher","unstructured":"Okada A, Tateishi E, Morita Y, Ohta-Ogo K, Izumi C. Serial 99m\u00a0technetium pyrophosphate scintigraphy and multimodality assessments after different doses of tafamidis for variant transthyretin cardiac amyloidosis. Circ Heart Fail. 2023;16(1):e009595. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.009595.","DOI":"10.1161\/CIRCHEARTFAILURE.122.009595"},{"key":"6459_CR24","doi-asserted-by":"crossref","unstructured":"Bellevre D, Bailliez A, Mar\u00e9chaux S, Manrique A, Mouquet F. First follow-up of cardiac amyloidosis treated by tafamidis, evaluated by absolute quantification in bone scintigraphy. JACC Case Rep. 2021;3:133\u20135.","DOI":"10.1016\/j.jaccas.2020.11.036"},{"key":"6459_CR25","doi-asserted-by":"publisher","unstructured":"Papathanasiou M, Kessler L, Bengel FM, Jakstaite AM, Kersting D, Varasteh Z, Luedike P, Carpinteiro A, Herrmann K, Rassaf T, Rischpler C. Regression of myocardial 99mTc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis. J Nucl Med. 2023;64(7):1083\u20131086. https:\/\/doi.org\/10.2967\/jnumed.122.265352.","DOI":"10.2967\/jnumed.122.265352"},{"key":"6459_CR26","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med. 2023;389(3):239\u2013250. https:\/\/doi.org\/10.1056\/NEJMoa2303765.","DOI":"10.1056\/NEJMoa2303765"},{"key":"6459_CR27","doi-asserted-by":"publisher","unstructured":"Minutoli F, Laudicella R, Baldari S. Monitoring of cardiac transthyretin amyloid load by [ 99m Tc]DPD scintigraphy: is it the end of the semi-quantitative evaluation? Amyloid. 2022;29(3):210. https:\/\/doi.org\/10.1080\/13506129.2022.2055460.","DOI":"10.1080\/13506129.2022.2055460"},{"key":"6459_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/13506129.2021.1991302","volume":"29","author":"JC Ross","year":"2022","unstructured":"Ross JC, Hutt DF, Burniston M, Grigore SF, Fontana M, Page J, et al. The role of serial 99m Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. Amyloid. 2022;29:38\u201349.","journal-title":"Amyloid"},{"key":"6459_CR29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","volume":"25","author":"MA Stats","year":"2016","unstructured":"Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol. 2016;25:413\u20137.","journal-title":"Cardiovasc Pathol"},{"key":"6459_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijcard.2022.01.036","volume":"352","author":"U Thelander","year":"2022","unstructured":"Thelander U, Westermark GT, Antoni G, Estrada S, Zancanaro A, Ihse E, et al. Cardiac microcalcifications in transthyretin (ATTR) amyloidosis. Int J Cardiol. 2022;352:84\u201391.","journal-title":"Int J Cardiol"},{"key":"6459_CR31","doi-asserted-by":"crossref","unstructured":"Captur G, Manisty CH, Raman B, Marchi A, Wong TC, Ariga R, et al. Maximal wall thickness measurement in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2021;14:2123\u201334.","DOI":"10.1016\/j.jcmg.2021.03.032"},{"key":"6459_CR32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u201316.","journal-title":"N Engl J Med"},{"key":"6459_CR33","doi-asserted-by":"publisher","unstructured":"Singh BM, Bohara N, Gautam K, Basnet M, Kc S, Kc B, Raut A, Phudong A, Gautam J. A Systematic review of tafamidis in patients with transthyretin amyloid cardiomyopathy. Cureus. 2021;13(9):e18221. https:\/\/doi.org\/10.7759\/cureus.18221.","DOI":"10.7759\/cureus.18221"},{"key":"6459_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/13506129.2019.1575201","volume":"26","author":"JN Buxbaum","year":"2019","unstructured":"Buxbaum JN. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials. Amyloid. 2019;26:55\u201365.","journal-title":"Amyloid"},{"key":"6459_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","volume":"25","author":"JC Ross","year":"2018","unstructured":"Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, et al. Quantitation of 99m Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid. 2018;25:203\u201310.","journal-title":"Amyloid"},{"key":"6459_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Bengel F, Brito D, Damy T, Duca F, Dorbala S, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23:895\u2013905.","journal-title":"Eur J Heart Fail"},{"key":"6459_CR37","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jjcc.2020.07.003","volume":"76","author":"SH Kim","year":"2020","unstructured":"Kim SH, Kim YS, Kim S-J. Diagnostic performance of PET for detection of cardiac amyloidosis: a systematic review and meta-analysis. J Cardiol. 2020;76:618\u201325.","journal-title":"J Cardiol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06459-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T21:30:02Z","timestamp":1705613402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06459-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6459"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06459-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.L.A. Nienhuis has received consultancy and speaker fee from Pfizer and Alnylam. P. van der Meer has received grant support and\/or consultancy fees from Novartis, Pharma Nord, Pfizer, Ionis, Astra Zeneca, Vifor Pharma, Pharmacosmos, BridgeBio, and NovoNordisk. R.H.J.A. Slart has received grant support of Pfizer and Siemens Healthineers. C. Knackstedt has received consultancy and speaker fees from Pfizer and Alnylam and grant support from Pfizer. A. Hirsch has received a research grant and consultancy fees from GE Healthcare and speaker fees from GE Healthcare and Bayer. He is also a member of the medical advisory board of Medis Medical Imaging Systems and was the MRI corelab supervisor of Cardialysis BV. M. Michels has received grant support and\/or consultancy fees from Bristol Meyers Squibb, Pfizer, and Cytokinetics. P.A. van der Zwaag has received consultancy and speaker fees from Pfizer, and Alnylam. M.I.F.J. Oerlemans has received consultancy fees from Alnylam, Pfizer, Johnson & Johnson, and Novartis paid to the University Medical Centre Utrecht, outside the current work. The other authors have no disclosures of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in compliance with the Declaration of Helsinki. The study was approved by the institutional review board of the UMCG (Registration number: 202100406).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Requirement for consent was waived by the institutional review board of the UMCG (Registration number: 202100406).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}